The increasing release of data on anti-obesity drugs, including Novo Nordisk’s Wegovy (NVO) trials, is fueling excitement around these medications. However, concerns are also being raised about their long-term effects on patients and the future of weight management, given the enormous market potential for these drugs.
As part of Yahoo Finance’s Healthcare week, Dr. Angela Fitch, President of the Obesity Medicine Association, sat down with Anjalee Khemlani to discuss the long-term effects of these drugs and the importance of proper care in treating obesity, with or without medications.
Dr. Fitch addresses the question of whether these medications will truly be successful, considering the challenges patients face in staying on them. She points out that the recent data may be somewhat misleading because many patients have difficulty adhering to medication regimens. While telemedicine and other companies have made it easier for patients to access these drugs, it’s crucial to ensure they receive comprehensive care from a healthcare professional. Simply obtaining the drug via text message is not enough. Dr. Fitch emphasizes that treating obesity as a chronic disease requires a holistic approach, involving ongoing medical supervision and support. With this approach, more patients will be able to tolerate these medications and remain on treatment.
For more expert insights and the latest market developments in the field, viewers can watch the full episode of Yahoo Finance Live.
